Prosztatarák: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• STAT3 0
• PI3K 2
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• MAPK 0
• AMPK 0
• CDK4/6 4
• HER2 6
• NRF2 0
• FAK 0
• PPAR 0
• YAP 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

18+ intézményből 18, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · P01

  Understanding and targeting treatment-associated lineage plasticity in cancer

  Columbia University Health Sciences· New York, Egyesült Államok· 2 729 322 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  The role of GRK3-HDAC2 epigenetic pathway in neuroendocrine prostate cancer and immune evasion

  Methodist Hospital Research Institute· Houston, Egyesült Államok· 514 864 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R01

  Elucidating upstream and downstream NUAK2 mechanisms in neuroendocrine prostate cancer

  Augusta University· Augusta, Egyesült Államok· 518 589 USD awarded in fiscal year 2026· until 2031. aug.

• NIH NCI · R56

  The role of AKT isoform-preferred substrates in prostate cancer aggressiveness

  Roswell Park Cancer Institute Corp· Buffalo, Egyesült Államok· 130 125 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NCI · R01

  Analysis of epithelial heterogeneity and plasticity in prostate development and cancer

  Columbia University Health Sciences· New York, Egyesült Államok· 613 866 USD awarded in fiscal year 2026· until 2031. júl.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Németország· EU contribution 202 125 EUR· until 2029. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Törökország· EU contribution 398 612 EUR· until 2029. dec.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Görögország· EU contribution 796 590 EUR· until 2030. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Dánia· EU contribution 247 553 EUR· until 2028. dec.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, Egyesült Királyság· EU contribution 260 348 EUR· until 2028. szept.

10 of 74 running projects, newest first. Listed amounts together: 30,6 M USD + 116,1 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors

  NCT04557449· Pfizer· Forrás

• A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

  NCT05288166· Eli Lilly and Company· Forrás

• Abemaciclib With or Without Atezolizumab for mCRPC

  NCT04751929· Dana-Farber Cancer Institute· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 39
• CRISPR-Cas Systems 15
• Gene Expression Profiling 154
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 465
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 62

• Integration of bulk RNA-seq data with single-cell RNA-seq data to identify urinary biomarkers derived from prostate tumor tissues.

  BMC Urol, 2026. aug.

• Integrated miRNA Sequencing and Network Analysis Reveal a Molecular Continuum Between Peritumoral and Tumor Tissue in Prostate Cancer.

  Int J Mol Sci, 2026. júl.

• RNAlater-compatible protocol for nuclei isolation from radical prostatectomy prostate cancer resections, enabling single-nucleus resolution RNA-seq.

  Sci Rep, 2026. jún.

• Single-cell and spatial RNA sequencing in prostate cancer.

  Nat Rev Urol, 2026. máj.

• CEP-IP: An explainable framework for cell subpopulation identification in single-cell transcriptomics.

  Comput Methods Programs Biomed, 2026. ápr.

• Advances in the identification of novel cell signatures in benign prostatic hyperplasia and prostate cancer using single-cell RNA sequencing.

  Front Immunol, 2026. jan.

• Unlocking single-cell level and continuous whole-slide insights in spatial transcriptomics with PanoSpace.

  Nat Comput Sci, 2026. jan.

• Exploring the key functions of T cells and the regulation of the immune microenvironment in prostate cancer using single-cell RNA sequencing and bulk RNA sequencing.

  Autoimmunity, 2025. dec.

• Exploring tumor dynamics and responses of prostate cancer to IL-27 based treatment combinations through biodynamic imaging and RNA sequencing analyses.

  Sci Rep, 2025. nov.

• Integrated Analysis of Single-Cell RNA Sequencing and Machine Learning Reveals a T Cell-Specific PANoptosis Signature Predicting Prognosis and Immunotherapy in Prostate Cancer.

  Hum Mutat, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.